Last reviewed · How we verify
NCT05513404
The Scottish Fruit Study
NA trial testing Honeyberry in Postprandial Hypoglycemia in 24 participants. Completed in 31 March 2024.
31 March 2024
Quick facts
| Lead sponsor | University of Aberdeen |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 15 August 2022 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Honeyberry
- Cherry
- Raspberry
Conditions studied
- Postprandial Hypoglycemia — all drugs for Postprandial Hypoglycemia →
- Age-Related Memory Disorders — all drugs for Age-Related Memory Disorders →
Sponsor
University of Aberdeen
Who can join
Adults 40 to 70, any sex, with Postprandial Hypoglycemia or Age-Related Memory Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if new varieties of fruits grown in Scotland which can adapt better to climate change namely, honeyberries and cherries, have the same health benefits as established fruits such as raspberries. To do this we will investigate the effects of consuming honeyberries, cherries, and raspberries on short term changes in blood glucose, and on short term memory.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05513404
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postprandial Hypoglycemia
Currently open trials in the same condition.
- NCT05401578 — Canakinumab for the Treatment of Postprandial Hypoglycemia · Phase 3 · recruiting
Other University of Aberdeen trials
Trials by the same sponsor.
- NCT07070765 — Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity · NA · not yet recruiting
- NCT07065383 — Rebalancing the Fat Content of the Heart and Muscles · NA · recruiting
- NCT06735573 — Protein, Sarcopenic Obesity, and COPD · not yet recruiting
- NCT06714656 — Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young · NA · recruiting
- NCT06721312 — Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relatio · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05513404 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aberdeen
- Last refreshed: 9 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05513404.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing